# Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

> **NCT03295227** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 37 (estimated)

## Conditions studied

- Stage III Thymoma AJCC v8
- Stage IIIA Thymoma AJCC v8
- Stage IIIB Thymoma AJCC v8
- Stage IV Thymoma AJCC v8
- Stage IVA Thymoma AJCC v8
- Stage IVB Thymoma AJCC v8
- Unresectable Thymic Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03295227
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-12-06
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03295227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03295227, "Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT03295227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*